Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review

• Published in: Graefe's archive for clinical and experimental ophthalmology Vol. 262; no. 3; pp. 717 - 752
• Main Authors: Ntentakis, Dimitrios P., Correa, Victor San Martin Carvalho, Ntentaki, Anastasia Maria, Delavogia, Eleni, Narimatsu, Toshio, Efstathiou, Nikolaos E., Vavvas, Demetrios G.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2024; Springer Nature B.V
• Subjects: Aged; Agonists; Amylin; Antidiabetics; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic retinopathy; Diabetic Retinopathy - complications; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Edema; Glucagon; Glucagon-like peptide 1; Glucose; Glucose transporter; Humans; Hypoglycemic Agents - therapeutic use; Kidney diseases; Literature reviews; Macular Edema; Medicine; Medicine & Public Health; Ophthalmology; Peroxisome proliferator-activated receptors; Retina; Retinopathy; Retrospective Studies; Review Article; α-Glucosidase; Type 2 diabetes; Diabetic retinopathy; Diabetic retinopathy complications; Newer-generation anti-diabetics
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-023-06236-5

Diabetic retinopathy (DR) is the leading etiology of blindness in the working population of the USA. Its long-term management relies on effective glycemic control. Seven anti-diabetic classes have been introduced for patients with type 2 diabetes (T2D) in the past two decades, with different glucose-lowering and cardiovascular benefits. Yet, their effects specifically on DR have not been studied in detail. A systematic review of the literature was conducted to investigate this topic, focusing on the available clinical data for T2D. Published studies were evaluated based on their level of statistical evidence, as long as they incorporated at least one endpoint or adverse event pertaining to retinal health. Fifty nine articles met our inclusion criteria and were grouped per anti-diabetic class as follows: alpha-glucosidase inhibitors (1), peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists (8), amylin analogs (1), glucagon-like peptide-1 (GLP-1) receptor agonists (28), dipeptidyl peptidase 4 (DPP-4) inhibitors (9), and sodium glucose co-transporter-2 (SGLT-2) inhibitors (9), plus one retrospective study and two meta-analyses evaluating more than one of the aforementioned anti-diabetic categories. We also reviewed publicly-announced results of trials for the recently-introduced class of twincretins. The available data indicates that most drugs in the newer anti-diabetic classes are neutral to DR progression; however, there are subclasses differences in specific drugs and T2D populations. In particular, there is evidence suggesting there may be worse diabetic macular edema with PPAR-gamma agonists, potential slight DR worsening with semaglutide (GLP-1 receptor agonist), and potential slight increase in the incidence of retinal vein occlusion in elderly and patients with advanced kidney disease receiving SGLT-2 inhibitors. All these warrant further investigation. Longer follow-up and systematic assessment of at least one DR-related endpoint are highly recommended for all future trials in the T2D field, to ultimately address this topic. Graphical abstract